Generation of Human Liver Chimeric Mice with Hepatocytes from Familial Hypercholesterolemia Induced Pluripotent Stem Cells

Stem Cell Reports

Volumn 8, Issue 3, 2017, Pages 605-618

  Yang, Jiayin ^a,c   Wang, Yu ^b,c   Zhou, Ting ^b,c   Wong, Lai Yung ^a   Tian, Xiao Yu ^d   Hong, Xueyu ^a   Lai, Wing Hon ^a   Au, Ka Wing ^a   Wei, Rui ^a   Liu, Yuqing ^b,c   Cheng, Lai Hung ^d   Liang, Guichan ^b,c   Huang, Zhijian ^b,c   Fan, Wenxia ^b,c   Zhao, Ping ^b,c   Wang, Xiwei ^b,c   Ibañez, David P ^b,c   Luo, Zhiwei ^b,c   Li, Yingying ^b,c   Zhong, Xiaofen ^b,c   Chen, Shuhan ^b,c   Wang, Dongye ^b,c   Li, Li ^b   Lai, Liangxue ^b   Qin, Baoming ^b,c   Bao, Xichen ^b,c   Hutchins, Andrew P ^e   Siu, Chung Wah ^a,c   Huang, Yu ^d   Esteban, Miguel A ^b,c   Tse, Hung Fat ^a,c,f   more..

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

Author keywords

endothelium dependent vasodilation; familial hypercholesterolemia; genetic engineering; hepatocytes; human liver chimeric mice; induced pluripotent stem cells; LDL receptor; PCSK9 antibodies; statins

Indexed keywords

ALIROCUMAB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INDUCED PLURIPOTENT STEM CELL; LIPID TRANSPORT; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; VASODILATATION; ANIMAL; CHIMERA; CYTOLOGY; GENETICS; HETEROZYGOTE; KNOCKOUT MOUSE; METABOLISM; MUTATION; PEDIGREE; TRANSGENIC MOUSE;

ANIMALS; CELL DIFFERENTIATION; CHIMERA; CHOLESTEROL, LDL; HEPATOCYTES; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INDUCED PLURIPOTENT STEM CELLS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PEDIGREE; PROPROTEIN CONVERTASE 9; RECEPTORS, LDL;

EID: 85014121579     PISSN: 22136711     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.stemcr.2017.01.027     Document Type: Article

References (47)

1. Aggoun, Y., Bonnet, D., Sidi, D., Girardet, J.P., Brucker, E., Polak, M., Safar, M.E., Levy, B.I., Arterial mechanical changes in children with familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 20 (2000), 2070–2075.
2. Azuma, H., Paulk, N., Ranade, A., Dorrell, C., Al-Dhalimy, M., Ellis, E., Strom, S., Kay, M.A., Finegold, M., Grompe, M., Robust expansion of human hepatocytes in Fah(-/-)/Rag2(-/-)/Il2rg(-/-) mice. Nat. Biotechnol. 25 (2007), 903–910.
3. Basma, H., Soto-Gutierrez, A., Yannam, G.R., Liu, L., Ito, R., Yamamoto, T., Ellis, E., Carson, S.D., Sato, S., Chen, Y., et al. Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. Gastroenterology 136 (2009), 990–999.
4. Benda, C., Zhou, T., Wang, X., Tian, W., Grillari, J., Tse, H.-F., Grillari-Voglauer, R., Pei, D., Esteban, M.A., Urine as a source of stem cells. Adv. Biochem. Eng. Biotechnol. 129 (2013), 19–32.
5. Bissig, K.D., Wieland, S.F., Tran, P., Isogawa, M., Le, T.T., Chisari, F.V., Verma, I.M., Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 120 (2010), 924–930.
6. Bissig-Choisat, B., Wang, L., Legras, X., Saha, P.K., Chen, L., Bell, P., Pankowicz, F.P., Hill, M.C., Barzi, M., Leyton, C.K., et al. Development and rescue of human familial hypercholesterolaemia in a xenograft mouse model. Nat. Commun., 6, 2015, 7339.
7. Brown, M.S., Goldstein, J.L., A receptor-mediated pathway for cholesterol homeostasis. Science 232 (1986), 34–47.
8. Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., Darius, H., Lewis, B.S., Ophuis, T.O., Jukema, J.W., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372 (2015), 2387–2397.
9. Cantz, T., Sharma, A.D., Ott, M., Concise review: cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments. Stem Cells 33 (2015), 1055–1062.
10. Carpentier, A., Tesfaye, A., Chu, V., Nimgaonkar, I., Zhang, F., Lee, S.B., Thorgeirsson, S.S., Feinstone, S.M., Liang, T.J., Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J. Clin. Invest. 124 (2014), 4953–4964.
11. Cayo, M.A., Cai, J., DeLaForest, A., Noto, F.K., Nagaoka, M., Clark, B.S., Collery, R.F., Si-Tayeb, K., Duncan, S.A., JD induced pluripotent stem cell–derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 56 (2012), 2163–2171.
12. Chen, Y.F., Tseng, C.Y., Wang, H.W., Kuo, H.C., Yang, V.W., Lee, O.K., Rapid generation of mature hepatocyte-like cells from human induced pluripotent stem cells by an efficient three-step protocol. Hepatology 55 (2012), 1193–1203.
13. Chen, Y., Li, Y.F., Wang, X., Zhang, W., Sauer, V., Chang, C.J., Han, B., Tchaikovskaya, T., Avsar, Y., Tafaleng, E., et al. Amelioration of hyperbilirubinemia in Gunn rats after transplantation of human induced pluripotent stem cell-derived hepatocytes. Stem Cell Rep. 5 (2015), 22–30.
14. Dormuth, C.R., Filion, K.B., Paterson, J.M., James, M.T., Teare, G.F., Raymond, C.B., Rahme, E., Tamim, H., Lipscombe, L., Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ, 348, 2014, g3244.
15. Dubuc, G., Chamberland, A., Wassef, H., Davignon, J., Seidah, N.G., Bernier, L., Prat, A., Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 1454–1459.
16. Endo, A., The discovery and development of HMG-CoA reductase inhibitors. J. Lipid. Res. 33 (1992), 1569–1582.
17. Grskovic, M., Javaherian, A., Strulovici, B., Daley, G.Q., Induced pluripotent stem cells—opportunities for disease modelling and drug discovery. Nat. Rev. Drug Discov. 10 (2011), 915–929.
18. Ishibashi, S., Brown, M.S., Goldstein, J.L., Gerard, R.D., Hammer, R.E., Herz, J., Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92 (1993), 883–893.
19. Kajiwara, M., Aoi, T., Okita, K., Takahashi, R., Inoue, H., Takayama, N., Endo, H., Eto, K., Toguchida, J., Uemoto, S., et al. Donor-dependent variations in hepatic differentiation from human-induced pluripotent stem cells. Proc. Natl. Acad. Sci. USA 109 (2012), 12538–12543.
20. Khoo, K.L., van Acker, P., Defesche, J.C., Tan, H., van de Kerkhof, L., Heijnen-van Eijk, S.J., Kastelein, J.J., Deslypere, J.P., Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia. Clin. Genet. 58 (2000), 98–105.
21. Legrand, N., Ploss, A., Balling, R., Becker, P.D., Borsotti, C., Brezillon, N., Debarry, J., de Jong, Y., Deng, H.K., Di Santo, J.P., et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6 (2009), 5–9.
22. Li, W., Wang, X., Fan, W., Zhao, P., Chan, Y.C., Chen, S., Zhang, S., Guo, X., Zhang, Y., Li, Y., et al. Modeling abnormal early development with induced pluripotent stem cells from aneuploid syndromes. Hum. Mol. Genet. 21 (2012), 32–45.
23. Liu, H., Kim, Y., Sharkis, S., Marchionni, L., Jang, Y.Y., In vivo liver regeneration potential of human induced pluripotent stem cells from diverse origins. Sci. Transl. Med., 3, 2011, 82ra39.
24. Maxwell, K.N., Fisher, E.A., Breslow, J.L., Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA 102 (2005), 2069–2074.
25. Moehle, E.A., Rock, J.M., Lee, Y.-L., Jouvenot, Y., DeKelver, R.C., Gregory, P.D., Urnov, F.D., Holmes, M.C., Targeted gene addition into a specified location in the human genome using designed zinc finger nucleases. Proc. Natl. Acad. Sci. USA 104 (2007), 3055–3060.
26. Ramakrishnan, V.M., Yang, J.Y., Tien, K.T., McKinley, T.R., Bocard, B.R., Maijub, J.G., Burchell, P.O., Williams, S.K., Morris, M.E., Hoying, J.B., et al. Restoration of physiologically responsive low-density lipoprotein receptor-mediated endocytosis in genetically deficient induced pluripotent stem cells. Sci. Rep., 5, 2015, 13231.
27. Rashid, S.T., Corbineau, S., Hannan, N., Marciniak, S.J., Miranda, E., Alexander, G., Huang-Doran, I., Griffin, J., Ahrlund-Richter, L., Skepper, J., et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120 (2010), 3127–3136.
28. Reiner, Z., Management of patients with familial hypercholesterolaemia. Nat. Rev. Cardiol. 12 (2015), 565–575.
29. Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., El Shahawy, M., Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372 (2015), 1489–1499.
30. Roth, E.M., McKenney, J.M., Hanotin, C., Asset, G., Stein, E.A., Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367 (2012), 1891–1900.
31. Shiomi, M., Ito, T., The Watanabe heritable hyperlipidemic (WHHL) rabbit, its characteristics and history of development: a tribute to the late Dr. Yoshio Watanabe. Atherosclerosis 207 (2009), 1–7.
32. Si-Tayeb, K., Idriss, S., Champon, B., Caillaud, A., Pichelin, M., Arnaud, L., Lemarchand, P., Le May, C., Zibara, K., Cariou, B., Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis. Model. Mech. 9 (2016), 81–90.
33. Sniderman, A.D., Tsimikas, S., Fazio, S., The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies. J. Am. Coll. Cardiol. 63 (2014), 1935–1947.
34. Soldner, F., Laganière, J., Cheng, A.W., Hockemeyer, D., Gao, Q., Alagappan, R., Khurana, V., Golbe, L.I., Myers, R.H., Lindquist, S., Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146 (2011), 318–331.
35. Stein, E.A., Honarpour, N., Wasserman, S.M., Xu, F., Scott, R., Raal, F.J., Effect of the PCSK9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128 (2013), 2113–2120.
36. Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., Roden, M., Stein, E., Tokgozoglu, L., Nordestgaard, B.G., et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur. Heart J. 36 (2015), 1012–1022.
37. Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., Yamanaka, S., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
38. Tian, X.Y., Wong, W.T., Xu, A., Chen, Z.Y., Lu, Y., Liu, L.M., Lee, V.W., Lau, C.W., Yao, X., Huang, Y., Rosuvastatin improves endothelial function in db/db mice: role of angiotensin II type 1 receptors and oxidative stress. Br. J. Pharmacol. 164 (2011), 598–606.
39. Vanhoutte, P.M., Zhao, Y., Xu, A., Leung, S.W., Thirty years of saying NO: sources, fate, actions, and misfortunes of the endothelium-derived vasodilator mediator. Circ. Res. 119 (2016), 375–396.
40. Wiegman, A., Hutten, B.A., de Groot, E., Rodenburg, J., Bakker, H.D., Buller, H.R., Sijbrands, E.J., Kastelein, J.J., Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 292 (2004), 331–337.
41. Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, I.I., Thomson, J.A., Human induced pluripotent stem cells free of vector and transgene sequences. Science 324 (2009), 797–801.
42. Yu, J., Chau, K.F., Vodyanik, M.A., Jiang, J., Jiang, Y., Efficient feeder-free episomal reprogramming with small molecules. PLoS One, 6, 2011, e17557.
43. Yusa, K., Rashid, S.T., Strick-Marchand, H., Varela, I., Liu, P.Q., Paschon, D.E., Miranda, E., Ordonez, A., Hannan, N.R., Rouhani, F.J., et al. Targeted gene correction of alpha1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478 (2011), 391–394.
44. Zhang, S., Chen, S., Li, W., Guo, X., Zhao, P., Xu, J., Chen, Y., Pan, Q., Liu, X., Zychlinski, D., et al. Rescue of ATP7B function in hepatocyte-like cells from Wilson's disease induced pluripotent stem cells using gene therapy or the chaperone drug curcumin. Hum. Mol. Genet. 20 (2011), 3176–3187.
45. Zhang, L.W., McCabe, T., Condra, J.H., Ni, Y.G., Peterson, L.B., Wang, W.R., Strack, A.M., Wang, F.B., Pandit, S., Hammond, H., et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int. J. Biol. Sci. 8 (2012), 310–327.
46. Zhou, T., Benda, C., Duzinger, S., Huang, Y., Li, X., Li, Y., Guo, X., Cao, G., Chen, S., Hao, L., Generation of induced pluripotent stem cells from urine. J. Am. Soc. Nephrol. 22 (2011), 1221–1228.
47. Zhou, T., Benda, C., Dunzinger, S., Huang, Y., Ho, J.C., Yang, J., Wang, Y., Zhang, Y., Zhuang, Q., Li, Y., Generation of human induced pluripotent stem cells from urine samples. Nat. Protoc. 7 (2012), 2080–2089.